Related references
Note: Only part of the references are listed.Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Erin M. Parry et al.
NATURE MEDICINE (2023)
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. R. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
A. M. Frustaci et al.
HEMATOLOGICAL ONCOLOGY (2023)
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome
M. S. Davids et al.
HEMATOLOGICAL ONCOLOGY (2023)
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION
C. Carlo‐Stella et al.
HEMATOLOGICAL ONCOLOGY (2023)
EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1
B. Eichhorst et al.
HEMATOLOGICAL ONCOLOGY (2023)
Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
Constantine Tam et al.
HEMASPHERE (2023)
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Matthew S. Davids et al.
BLOOD (2022)
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Herve Tilly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
Valentin Ortiz-Maldonado et al.
FRONTIERS IN ONCOLOGY (2022)
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elias Campo et al.
BLOOD (2022)
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
Andrea Visentin et al.
HAEMATOLOGICA (2022)
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Deborah M. Stephens et al.
CLINICAL CANCER RESEARCH (2022)
Biology and Treatment of Richter Transformation
Adalgisa Condoluci et al.
FRONTIERS IN ONCOLOGY (2022)
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Xavier Chauchet et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
A phase two study of high dose blinatumomab in Richter's syndrome
Philip A. Thompson et al.
LEUKEMIA (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
William G. Wierda et al.
BLOOD (2022)
Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
Romain Guieze et al.
BLOOD (2022)
Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
Arnon P. Kater et al.
BLOOD (2022)
Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
Stephen E. Spurgeon et al.
BLOOD (2022)
First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma
Eliza Hawkes et al.
BLOOD (2022)
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
Florian Bouclet et al.
ANNALS OF HEMATOLOGY (2021)
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models
Tiziana Vaisitti et al.
BLOOD (2021)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (vol 24, pg 563, 2018)
Joseph A. Fraietta et al.
NATURE MEDICINE (2021)
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation
Haesook T. Kim et al.
HAEMATOLOGICA (2021)
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome
Alex F. Herrera et al.
BLOOD ADVANCES (2021)
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation
Oscar B. Lahoud et al.
BLOOD ADVANCES (2021)
Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies
Katharine L. Lewis et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center
Yucai Wang et al.
HAEMATOLOGICA (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Pembrolizumab in relapsed or refractory Richter syndrome
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
Adam S. Kittai et al.
BLOOD ADVANCES (2020)
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment
Kristo Marvyin et al.
BMJ CASE REPORTS (2020)
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome
Jennifer L. Crombie et al.
BLOOD (2020)
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
Andrea Visentin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
Jaco A. C. van Bruggen et al.
BLOOD (2019)
Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway
Andrea Lenartova et al.
CANCER EPIDEMIOLOGY (2019)
Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia A Case Series and Review of the Literature
Bianca M. Van Der Nest et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation
Joanna M. Rhodes et al.
PET CLINICS (2019)
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT) A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness
Rong He et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D. Reiff et al.
CANCER DISCOVERY (2018)
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
Kerry A. Rogers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Richter transformation in the era of novel agents
Wei Ding
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
Matthew Steven Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
An 18F-FDG-PET maximum standardized uptake value>10 represents a novel valid marker for discerning Richter's Syndrome
Anne-Sophie Michallet et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The efficacy of ibrutinib in the treatment of Richter syndrome
Mazie Tsang et al.
BLOOD (2015)
Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study
Eric Durot et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease
F. R. Mauro et al.
LEUKEMIA (2015)
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
Petra Langerbeins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Lorenzo Falchi et al.
BLOOD (2014)
Serum Albumin Level <32 g/l on Day 30 Can Predicts Higher Risk of Non-Relapse Mortality in Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation
Feras Alfraih et al.
BLOOD (2014)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
Sameer A. Parikh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Apostolia M. Tsimberidou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Giulia Fabbri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome
Davide Rossi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Kate Cwynarski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi et al.
BLOOD (2011)
被撤回的出版物: Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (accelerated chronic lymphocytic leukemia) with aggressive clinical behavior (Retracted Article. See vol 95, pg 1620, 2010)
Eva Gine et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IgVH mutational status and clonality analysis of Richter's transformation -: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution
Zhengrong Mao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
AM Tsimberidou et al.
CANCER (2003)
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
AM Tsimberidou et al.
LEUKEMIA & LYMPHOMA (2002)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
BS Dabaja et al.
LEUKEMIA & LYMPHOMA (2001)
Share Paper
